Product Details
Synonyms
GPC3, OCI5, Glypican-3, GTR2-2, MXR7, DGSX, SDYS , SGB, SGBS, SGBS1
Source
Human Glypican 3 Protein, Llama IgG2b Fc Tag (GP3-H5257) is expressed from human 293 cells (HEK293). It contains AA Gln 25 - His 559 (Accession # P51654-1).
Predicted N-terminus: Gln 25 & Ser 359
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a llama IgG2b Fc tag at the C-terminus.
The protein has a calculated MW of 38.1 kDa & 50.5 kDa. The protein migrates as 40 kDa, 60 kDa and 100-120 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human Glypican 3 Protein, Llama IgG2b Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Human FGF basic, premium grade (Cat. No. BFF-H4117) at 1 μg/mL (100 μL/well) can bind Human Glypican 3 Protein, Llama IgG2b Fc Tag (Cat. No. GP3-H5257) with a linear range of 0.6-39 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Glypican-3
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
57 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















